Li Xin, Rong Kewei, Huang Yunfei, Zhao Zhijie, Xu Changyang, Lin Li, Zhang Yuqi, Yan Yingjie, Huang Wenyi, Zhang Yichi, Li Li, Hou Mengyuan, Chai Gang, Zhang Yan, Chen Xiaojun
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shanghai Institute of Plastic and Reconstructive Surgery, Shanghai, China.
FASEB J. 2025 Aug 31;39(16):e70930. doi: 10.1096/fj.202500432R.
Previous studies have identified miR-148a-3p as a regulator of both angiogenesis and osteogenesis. However, in vitro findings have been inconsistent. This study aimed to elucidate the role and mechanism of miR-148a-3p in bone physiology using miR-148a knockout (KO) mice. Compared to wild-type and heterozygous littermates, miR-148a KO mice demonstrated smaller body size but exhibited increased bone mass, enhanced type H vessel formation, and improved osteogenesis. In vitro experiments showed that miR-148a inhibited osteogenesis of ectomesenchymal stem cells and suppressed the proliferation, migration, as well as tube formation of bone endothelial cells. Multi-omics analyses of bone samples and primary bone endothelial cells, including bulk RNA-seq, proteomics, and scRNA-seq, indicated that Itga11 was regulated via mRNA degradation and identified as a key player in osteogenesis and a direct target of miR-148a-3p, as confirmed by dual-luciferase reporter assays, while Rcc2 was implicated in angiogenesis through Rac1. Both pathways converged to activate the PI3K/Akt pathway. In the bone defect model, antagomiR-148a facilitated bone repair by promoting angiogenesis-osteogenesis coupling, suggesting that miR-148a-3p suppression may serve as a potential therapeutic strategy for enhancing the bone healing process.
先前的研究已将miR-148a-3p鉴定为血管生成和成骨的调节因子。然而,体外研究结果并不一致。本研究旨在使用miR-148a基因敲除(KO)小鼠阐明miR-148a-3p在骨生理学中的作用和机制。与野生型和杂合子同窝小鼠相比,miR-148a基因敲除小鼠体型较小,但骨量增加、H型血管形成增强且成骨改善。体外实验表明,miR-148a抑制外间充质干细胞的成骨作用,并抑制骨内皮细胞的增殖、迁移以及管腔形成。对骨样本和原代骨内皮细胞进行的多组学分析,包括批量RNA测序、蛋白质组学和单细胞RNA测序,表明Itga11通过mRNA降解受到调控,并被确定为成骨的关键因子以及miR-148a-3p的直接靶点,双荧光素酶报告基因实验证实了这一点,而Rcc2通过Rac1参与血管生成。这两条途径都汇聚以激活PI3K/Akt途径。在骨缺损模型中,抗miR-148a通过促进血管生成-成骨偶联促进骨修复,这表明抑制miR-148a-3p可能是增强骨愈合过程的一种潜在治疗策略。